Paclitaxel Ameliorates Lipopolysaccharide-Induced Kidney Injury by Binding Myeloid Differentiation Protein-2 to Block Toll-Like Receptor 4–Mediated Nuclear Factor-κB Activation and Cytokine Production
Authors:
- 1 April 2013
- journal article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 345 (1) , 69-75
Abstract
Recent studies suggest that paclitaxel, an anticancer agent, may modulate the injury and inflammatory responses in normal tissues. However, the underlying mechanism is not fully understood. Here we have examined the effect of paclitaxel on lipopolysaccharide (LPS)–induced acute kidney injury (AKI) in mice and further studied the mechanism. At relatively low doses, paclitaxel protected against LPS-induced AKI and improved animal survival. The beneficial effects of paclitaxel were accompanied by the downregulation of tumor necrosis factor-α, interleukin-1, and interleukin-6 production. In cultured renal tubular HK-2 cells, paclitaxel decreased the DNA-binding activity of nuclear factor-κB (NF-κB) during LPS treatment, inhibited the degradation of the inhibitor of κB-α, and blocked the expression and activation of NF-κB p65. At the upstream level, paclitaxel reduced LPS-induced association of myeloid differentiation protein-2 (MD-2) with Toll-like receptor 4 (TLR4). In an in vitro assay, paclitaxel was shown to directly bind recombinant MD-2. The inhibitory effect of paclitaxel on NF-κB activation and cytokine expression disappeared in MD-2 knockdown cells, indicating that paclitaxel acts through MD-2. Collectively, these results suggest that paclitaxel may bind MD-2 to block MD-2/TLR4 association during LPS treatment, resulting in the suppression of NF-κB activation and inhibition of proinflammatory cytokine production.Keywords
This publication has 48 references indexed in Scilit:
- Pharmacological targets in the renal peritubular microenvironment: Implications for therapy for sepsis-induced acute kidney injuryPharmacology & Therapeutics, 2012
- Amelioration of Acute Kidney Injury in Lipopolysaccharide-Induced Systemic Inflammatory Response Syndrome by an Aldose Reductase Inhibitor, FidarestatPLOS ONE, 2012
- Low‐dose paclitaxel ameliorates fibrosis in the remnant kidney model by down‐regulating miR‐192The Journal of Pathology, 2011
- The role of spermidine/spermine N1-acetyltransferase in endotoxin-induced acute kidney injuryAmerican Journal of Physiology-Cell Physiology, 2010
- TLR2 ligands induce cardioprotection against ischaemia/reperfusion injury through a PI3K/Akt-dependent mechanismCardiovascular Research, 2010
- Regulation of mitochondrial dynamics in acute kidney injury in cell culture and rodent modelsJournal of Clinical Investigation, 2009
- Paclitaxel Binding to Human and Murine MD-2Journal of Biological Chemistry, 2008
- Bench-to-bedside review: Sepsis, severe sepsis and septic shock – does the nature of the infecting organism matter?Critical Care, 2008
- Structural Model of MD-2 and Functional Role of Its Basic Amino Acid Clusters Involved in Cellular Lipopolysaccharide RecognitionJournal of Biological Chemistry, 2004
- PATHOBIOLOGY OF LIPOPOLYSACCHARIDEJournal of Toxicology and Environmental Health, 1997